Dyne Therapeutics (NASDAQ:DYN) Shares Down 4.2% - Time to Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) fell 4.2% during trading on Friday . The stock traded as low as $29.73 and last traded at $29.82. 176,628 shares were traded during trading, a decline of 88% from the average session volume of 1,474,617 shares. The stock had previously closed at $31.13.

Analyst Upgrades and Downgrades

Several brokerages have commented on DYN. Morgan Stanley lifted their price objective on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an "overweight" rating in a research note on Wednesday, August 14th. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an "overweight" rating to a "neutral" rating and cut their target price for the company from $43.00 to $35.00 in a report on Thursday, October 24th. StockNews.com lowered shares of Dyne Therapeutics from a "hold" rating to a "sell" rating in a report on Monday, September 16th. Stifel Nicolaus lifted their target price on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a "buy" rating in a report on Friday, August 16th. Finally, Oppenheimer reaffirmed an "outperform" rating and set a $55.00 target price on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $50.82.

Dyne Therapeutics Trading Down 1.7 %

The firm's fifty day moving average is $31.66 and its 200 day moving average is $35.39. The company has a market cap of $3.12 billion, a PE ratio of -8.60 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.25). As a group, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Richard William Scalzo sold 1,390 shares of Dyne Therapeutics stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $48,024.50. Following the transaction, the senior vice president now directly owns 98,568 shares of the company's stock, valued at $3,405,524.40. The trade was a 1.39 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock in a transaction on Friday, September 20th. The shares were sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the completion of the transaction, the director now directly owns 234,127 shares in the company, valued at $8,533,929.15. The trade was a 25.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 176,257 shares of company stock valued at $6,193,718. 20.77% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Dyne Therapeutics

A number of institutional investors have recently modified their holdings of DYN. Nisa Investment Advisors LLC grew its position in Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company's stock valued at $26,000 after buying an additional 669 shares during the last quarter. Quantbot Technologies LP purchased a new position in Dyne Therapeutics in the 3rd quarter valued at $34,000. Point72 DIFC Ltd purchased a new position in Dyne Therapeutics in the 3rd quarter valued at $36,000. US Bancorp DE grew its position in Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company's stock valued at $49,000 after buying an additional 1,212 shares during the last quarter. Finally, Values First Advisors Inc. purchased a new position in Dyne Therapeutics in the 3rd quarter valued at $62,000. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.